Fabry disease in Latin America: Data from the fabry registry

JIMD Reports

Volumn 8, Issue , 2013, Pages 91-99

  Villalobos, J ^a,j   Politei, J M ^b   Martins, A M ^c   Cabrera, G ^d   Amartino, H ^e   Lemay, R ^f   Ospina, S ^g   Ordoñez, S Suarez ^h   Varas, C ⁱ  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Centro Médico Del Viso   (Argentina)

^e UNIVERSIDAD AUSTRAL   (Argentina)

^f GENZYME CORPORATION   (United States)

^g UNIVERSIDAD DEL ROSARIO   (Colombia)

^h Chiltern International   (Argentina)

ⁱ Hospital de San Pablo   (Chile)

^j UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

more..

Author keywords

Chronic kidney disease; Chronic kidney disease stage; Enzyme replacement therapy; Fabry disease; Left ventricular hypertrophy

Indexed keywords

EID: 85032357165     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2012_165     Document Type: Chapter

References (26)

1. Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86
2. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med 276:1163–1167
3. Branton MH, Schiffmann R, Sabnis SG et al (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81:122–138
4. Chamoles NA, Blanco M, Gaggioli D (2001) Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 308:195–196
5. Cole AL, Lee PJ, Hughes DA et al (2007) Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 30:943–951
6. Desnick RJ, Ioannou YA, Eng CM (2001) Alpha-Galactosidase A deficiency: Fabry disease. In: Scriver C, Beaudet A (eds) The metabolic bases of inherited disease. McGraw-Hill, New York, pp 3733–3774
7. Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease. N Engl J Med 345:9–16
8. Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547–1557
9. Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30
10. Gold KF, Pastores GM, Botteman MF et al (2002) Quality of life of patients with Fabry disease. Qual Life Res 11:317–327
11. Hopkin RJ, Bissler J, Banikazemi M et al (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550–555
12. Kolodny EH, Pastores GM (2002) Anderson-Fabry disease: extra-renal, neurologic manifestations. J Am Soc Nephrol 13(Suppl 2): S150–153
13. Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612
14. Linhart A, Kampmann C, Zamorano JL et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228–1235
15. Linthorst GE, Poorthuis BJ, Hollak CE (2008) Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results. J Am Coll Cardiol 51:2082, Author reply 82–83
16. Mehta A, Clarke JT, Giugliani R et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey. J Med Genet 46:548–552
17. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254
18. Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A (2005) Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol 33:164–168
19. Ortiz A, Cianciaruso B, Cizmarik M et al (2010) End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 25:769–775
20. Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743–2749
21. Schiffmann R, Warnock DG, Banikazemi M et al (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24:2102–2111
22. Sims K, Politei J, Banikazemi M, Lee P (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40:788–794
23. Waldeck S, Patel MR, Banikazemi M, Lemay R, Lee P (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11 (11):790–796
24. Waldek S, Germain DP, Wanner C, Warnock DG (2010) Enzyme replacement therapy for Fabry's disease. Lancet 375:1523, Author reply 23–24
25. Warnock DG, Ortiz A, Mauer M et al (2011) Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. doi:10.1093/ndt/gfr420
26. Wilcox WR, Oliveira JP, Hopkin RJ (2008) Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. Mol Genet Metab 93:112–128